| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | navitoclax:piperlongumine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.064 | 0.07 |
| mRNA | PFI-1 | GDSC1000 | pan-cancer | AAC | 0.058 | 0.07 |
| mRNA | SB-525334 | CTRPv2 | pan-cancer | AAC | -0.066 | 0.07 |
| mRNA | SB 216763 | GDSC1000 | pan-cancer | AAC | 0.066 | 0.08 |
| mRNA | CCT018159 | GDSC1000 | pan-cancer | AAC | 0.059 | 0.08 |
| mRNA | NG-25 | GDSC1000 | pan-cancer | AAC | 0.051 | 0.08 |
| mRNA | BRD-K49290616 | CTRPv2 | pan-cancer | AAC | 0.13 | 0.08 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | 0.063 | 0.08 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | 0.063 | 0.08 |
| mRNA | BAY 61-3606 | GDSC1000 | pan-cancer | AAC | 0.058 | 0.08 |